Journal
ONCOTARGETS AND THERAPY
Volume 14, Issue -, Pages 1501-1516Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S298958
Keywords
cGAS; STING; innate immunity; tumor; immunotherapy; drug discovery
Categories
Funding
- National Natural Science Foundation of China [81904231,82072978,82072979]
- China Postdoctoral Science Foundation [2020M672369]
- Natural Science Foundation of Hubei Province [2020CFB861]
Ask authors/readers for more resources
cGAS and STING play roles in recognizing abnormal DNA and regulating immune responses in the cytoplasm, with STING agonists showing promising application prospects in tumor treatment.
As a DNA receptor in the cytoplasm, cyclic GMP-AMP synthase (cGAS) contributes to the recognition of abnormal DNA in the cytoplasm and contributes to the stimulator of interferon genes (STING) signaling pathway. cGAS could mediate the expression of interferon-related genes, inflammatory-related factors, and downstream chemokines, thus initiating the immune response. The STING protein is a key effector downstream of the DNA receptor pathway. It is widely expressed across cell types such as immune cells,tumor cells, and stromal cells and plays a role in signal transduction for cytoplasmic DNA sensing and immunity. STING agonists, as novel agonists, are used in preclinical research and in the treatment of various tumors via clinical trials and have displayed attractive application prospects. Studying the cGAS-STING signaling pathway will deepen our understanding of tumor immunity and provide a basis for the research and development of antitumor drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available